Chin-Chou Huang1,2,3,4, Dau-Ming Niu5,6, Min-Ji Charng1,2. 1. Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital. 2. School of Medicine, National Yang Ming Chiao Tung University. 3. Cardiovascular Research Center, National Yang Ming Chiao Tung University. 4. Institute of Pharmacology, National Yang Ming Chiao Tung University. 5. Institute of Clinical Medicine, National Yang Ming Chiao Tung University. 6. Department of Pediatrics, Taipei Veterans General Hospital.
Abstract
AIM: Familial hypercholesterolemia (FH) is underdiagnosed in most countries. The genetic heterogeneity of FH requires an algorithm to efficiently integrate genetic testing into clinical practice. We aimed to report the spectrum of genetic mutations from patients with clinically diagnosed FH in Taiwan. METHODS: Patients with LDL-C＞190 mg/dL or those with probable or definite FH according to the Taiwan Lipid Guidelines underwent genetic testing. Samples from 750 index patients from the Taiwan FH registry were screened using custom-made mass spectrometry, followed by targeted next generation sequencing (NGS) and/or multiplex ligation-dependent probe amplification (MLPA) if found negative. RESULTS: The mean age of the patients was 52.4±15.1 years and 40.9% were male. Mutations were detected in 445 patients (59.3%). The distribution of mutations was as follows: LDLR (n=395), APOB (n=58), PCSK9 (n=0), and ABCG5 (n=3). The most common mutations were APOB c.10579 C＞T (p.R3527W) (12.6%), LDLR c.986 G＞A (p.C329Y) (11.5%), and LDLR c.1747 C＞T (p.H583Y) (10.8%). LDLR c.1187-10 G＞A (IVS 8-10) and APOB c.10580 G＞A (p.R3527Q) were detected using targeted NGS in Taiwan for the first time. Four novel mutations were identified, including LDLR c.1060＋2 T＞C (IVS 7＋2), LDLR c.1139 A＞C (p.E380A), LDLR c.1322 T＞C (p.A431T)＋c.1867 A＞G (p.I623V), and ABCG5 c.1337 G＞A (p.R447Q). CONCLUSION: LDLR and APOB, but not PCSK9, mutations were the major genetic causes of FH. Four novel mutations in LDLR or ABCG5 were identified. This genetic screening method using mass spectrometry, targeted NGS, and MLPA analysis provided an efficient algorithm for genetic testing for clinically diagnosed FH in Taiwan.
AIM: Familial hypercholesterolemia (FH) is underdiagnosed in most countries. The genetic heterogeneity of FH requires an algorithm to efficiently integrate genetic testing into clinical practice. We aimed to report the spectrum of genetic mutations from patients with clinically diagnosed FH in Taiwan. METHODS: Patients with LDL-C＞190 mg/dL or those with probable or definite FH according to the Taiwan Lipid Guidelines underwent genetic testing. Samples from 750 index patients from the Taiwan FH registry were screened using custom-made mass spectrometry, followed by targeted next generation sequencing (NGS) and/or multiplex ligation-dependent probe amplification (MLPA) if found negative. RESULTS: The mean age of the patients was 52.4±15.1 years and 40.9% were male. Mutations were detected in 445 patients (59.3%). The distribution of mutations was as follows: LDLR (n=395), APOB (n=58), PCSK9 (n=0), and ABCG5 (n=3). The most common mutations were APOB c.10579 C＞T (p.R3527W) (12.6%), LDLR c.986 G＞A (p.C329Y) (11.5%), and LDLR c.1747 C＞T (p.H583Y) (10.8%). LDLR c.1187-10 G＞A (IVS 8-10) and APOB c.10580 G＞A (p.R3527Q) were detected using targeted NGS in Taiwan for the first time. Four novel mutations were identified, including LDLR c.1060＋2 T＞C (IVS 7＋2), LDLR c.1139 A＞C (p.E380A), LDLR c.1322 T＞C (p.A431T)＋c.1867 A＞G (p.I623V), and ABCG5 c.1337 G＞A (p.R447Q). CONCLUSION: LDLR and APOB, but not PCSK9, mutations were the major genetic causes of FH. Four novel mutations in LDLR or ABCG5 were identified. This genetic screening method using mass spectrometry, targeted NGS, and MLPA analysis provided an efficient algorithm for genetic testing for clinically diagnosed FH in Taiwan.
Authors: Laurens F Reeskamp; Tycho R Tromp; Joep C Defesche; Aldo Grefhorst; Erik Sg Stroes; G Kees Hovingh; Linda Zuurbier Journal: Eur J Prev Cardiol Date: 2020-07-27 Impact factor: 7.804
Authors: Sabine Amsellem; Dorothée Briffaut; Alain Carrié; Jean Pierre Rabès; Jean Philippe Girardet; Alexandre Fredenrich; Philippe Moulin; Michel Krempf; Yves Reznik; Bernard Vialettes; Jean Luc de Gennes; Eric Brukert; Pascale Benlian Journal: Hum Genet Date: 2002-09-13 Impact factor: 4.132
Authors: Itziar Lamiquiz-Moneo; Lucía Baila-Rueda; Ana M Bea; Rocío Mateo-Gallego; Sofía Pérez-Calahorra; Victoria Marco-Benedí; Antonio Martín-Navarro; Emilio Ros; Montserrat Cofán; José Carlos Rodríguez-Rey; Miguel Pocovi; Ana Cenarro; Fernando Civeira Journal: J Clin Lipidol Date: 2017-10-04 Impact factor: 4.766